and joined the MJH Life Sciences team in April 2021. She graduated from Kent State University in 2018 with a bachelor's degree in journalism and a minor in sociology. Linda used to work as a creative writer for 

 and was a technical writer/regulatory specialist/purchasing agent at GM Industrial before coming on to the team. She enjoys reading, traveling, and learning new perspectives. You can reach her at 

Articles

Derm-Biome’s topical compounds have positive results in preclinical trial. 

Derm-Biome Announces Positive Preclinical Data in AD trials

Dermavant has announced it has dosed the first patient in its phase 3 trial evaluating tapinarof cream for the treatment of moderate to severe atopic dermatitis.  

Dosing Starts in Tapinarof AD Trials

A recent phase 3 trial investigated the safety of dupilumab as a treatment for severe atopic dermatitis in pediatric patients ages 6 to 11 years. 

Safety Study Evaluates Dupilumab in Pediatric Patients with Severe AD

Armand Butera is the assistant editor for 

. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining 

. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at 

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

Investigators Reveal Subtypes in Atopic Dermatitis Disease Activity

Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Podcasts

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.  

FDA Requiring Black Box Warning for Certain JAK Inhibitors  

Pfizer’s JADE DARE phase 3 trial met its coprimary and key secondary efficacy endpoints. 

Pfizer Reports Topline Results from Trial Comparing Abrocitinib to Dupilumab for AD

Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from the LIBERTY AD trial investigating dupilumab in pediatric patients ages 6 months to 5 years with atopic dermatitis. 

Dupilumab Demonstrates Safety, Efficacy in Pediatric AD Patients Ages 6 Months to 5 Years

Upadacitinib has been approved by the European Commision and becomes the first Janus kinase (JAK) inhibitor approved in the European Union for the treatment of moderate to severe atopic dermatitis in adult and pediatric patients.  

Upadacitinib Approved in EU for Atopic Dermatitis

Videos

In this video interview, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and why physicians should educate their patients about this type of inflammation.